←RETURN TO 2026 IPO RADAR DECK (135 OFFERINGS)COHORT STANDING: #113 of 135
Verified SEC Filing/Calendar Year 2026
NASDAQHealth Care
$ETRA
RANGE-BOUND (-50% to +50%)
Electra Therapeutics
Legal Entity: Electra Therapeutics, Inc.
OFFER PRICE$15.00
CURRENT PRICE
$8.99
CUMULATIVE RETURN
-41.70%
PRICING DATE: 9/18/2026SEC FILING SNAPSHOT
SECTION 01 // FORENSIC TEARDOWN
The Seagull Executive Verdict
SURVIVAL RATING: CRATER
WHAT THE BUSINESS DOES
Utilizes laboratory-engineered antibodies to modulate immune responses for cancer and autoimmune disease treatment. Pre-revenue cash burn operation.
THE WALL STREET PITCH
Pioneer in targeted immunology with a highly versatile biological platform.
THE COLD REALITY
Broken IPO suffering severe multiple compression due to public market impatience with early-stage preclinical assets.
SECTION 02 // CAPITAL ALLOCATION
Capital Formation & Float Scarcity
FLAG: TREASURY GROWTH
Gross Proceeds
$349.5M
Cash extracted from market
Post-Money Value
$1.6B
Total company valuation
Public Float %
22%
Shares available to public
Secondary Share %
0%
Insider cash extraction
CAPITAL USE ANALYSIS
Proceeds directed to balance sheet and operations.
SECTION 03 // SUPPLY SHOCK AUDITOR
Insider Lock-Up Expiration
VC DUMP RISK: ELEVATED
Expiration Calendar Date
2027-03-17
128 DAYS REMAINING
Supply Shock Multiplier
3.5x
Float expansion ratio upon unlock
Lockup Duration
180 Days
Contractual restriction window
SECTION 05 // COHORT BENCHMARK
Sector Peer & Cohort Telemetry
RANK: #113 of 135
2026 Cohort Standing
#113 of 135
Out of 135 total 2026 IPO offerings
Sector Median Return
+21.64%
Health Care sector midpoint
Sector Win Rate
78%
% of peer IPOs trading in profit
PERFORMANCE VS PEERS
Electra Therapeutics is currently trading below the Health Care sector median of 21.64%. Across the entire 2026 calendar year cohort, only 78% of Health Care offerings have sustained a positive return above their initial offer price.